Abstract 1005P
Background
Despite the availability of effective systemic therapies such as atezolizumab plus bevacizumab (A+B), the response rate remains unsatisfactory for patients with unresectable hepatocellular carcinoma with high tumor burden (uHTB-HCC). Our previous studies indicated that transarterial chemoembolization (TACE) combined with FOLFOX-based hepatic arterial infusion chemotherapy (HAIC) showed favorable results for HCC. This study aims to evaluate the efficacy and safety of A+B combined with TACE-HAIC for uHTB-HCC.
Methods
This retrospective study included uHTB-HCC (meeting at least one of the following criteria: beyond up-to-11, VP 3-4, extrahepatic metastases) pts who received TACE-HAIC followed by atezolizumab (1200mg IV) and bevacizumab (15mg/kg IV q4w) between March 2022 and December 2022. Efficacy was evaluated based on tumor response and survival rates, while safety was assessed by adverse events (AEs).
Results
Thirty-five uHTB-HCC pts received A+B combined with TACE-HAIC. Based on mRECIST criteria, the objective response rate (ORR) was 68.6%, with 8 (22.9%) pts achieved complete response, 16 (45.7%) partial response, 4 (11.4%) stable disease, and 7 (20.0%) progression disease. Additionally, 5 (14.3%) pts underwent curative hepatectomy after being converted to resectable HCC. The 1-year overall survival and progression-free survival rates were 94.3% and 71.4%, respectively. Of the 32 (91.4%) pts who experienced treatment-related adverse events (AEs), 13 (37.1%) had grade 3-4 AEs, but no treatment-related deaths occurred.
Table: 1005P
RECIST 1.1 (%) | mRECIST (%) | |
CR | 0 (0) | 8 (22.9) |
PR | 22 (62.9) | 16 (45.7) |
SD | 6 (17.1) | 4 (11.4) |
PD | 7 (20) | 7 (20.0) |
ORR | 22 (62.9) | 24 (68.6) |
Conclusions
The results suggested that A+B combined with TACE-HAIC was a promising treatment option for uHTB-HCC pts, given its excellent therapeutic efficacy and manageable adverse events.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
842P - Multicenter real-world study of newly diagnosed advanced-stage extranodal natural killer/T cell lymphoma (ENKTL): Proposal for intensive therapy
Presenter: Yu-Ce Wei
Session: Poster session 18
844P - Progression -free survival prediction of multiple myeloma patients in five European countries using machine learning models
Presenter: Maria Luisa Pleguezuelo Witte
Session: Poster session 18
845P - A machine learning based clinical platform for cancer subtyping and data integration in hematological malignancies
Presenter: Michelle Tang
Session: Poster session 18
846P - Artificial intelligence-driven identification of onco-hematology patients who may develop severe COVID-19
Presenter: Souad Assaad
Session: Poster session 18
847P - Fatal infections among leukemia patients
Presenter: Huijie Zhou
Session: Poster session 18
848P - Mortality after rasburicase vs allopurinol anti-hyperuricemia monotherapy in patients with liquid tumors
Presenter: Mitchell Cairo
Session: Poster session 18
849P - Long non-coding RNA signatures and their role in the progression of childhood T cell acute lymphoblastic leukemia
Presenter: Pankaj Sharma
Session: Poster session 18
850P - A zebrafish model of MYC-driven acute myeloid leukemia reveals that neutrophil resistance to oncogenic transformation depends on their ability to promote PP2A-mediated MYC proteasomal degradation
Presenter: Anna Maria Luciano
Session: Poster session 18
851P - Characterization of a zebrafish model of MYC-driven acute myeloid leukemia
Presenter: Anna Maria Luciano
Session: Poster session 18
852P - c-MAF-driven metabolic reprogramming mediates H3K27 hyperacetylation to regulate super enhancer-associated genes
Presenter: Phyllis SY Chong
Session: Poster session 18